Medical/Pharmaceuticals

Eurisotop Responds to Market Demand for Deuterated Chloroform

SACLAY, France, Sept. 22, 2020 /PRNewswire/ -- Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NM...

2020-09-22 22:00 1033

Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

RHEINBREITBACH and BONN, Germany, Sept. 22, 2020 /PRNewswire/ -- Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an...

2020-09-22 21:36 1237

Biorasi Commended by Frost & Sullivan for its Full-service Offering to Drive Rare Disease Patient Recruitment for CROs

SANTA CLARA, California, Sept. 22, 2020 /PRNewswire/ -- Based on its recent analysis of the North American contract research organization (CRO) market, Frost & Sullivan recognizesBiorasi, LLC with the 2020 North American Entrepreneurial Company of the Year Award. Biorasi's milestone-based, patie...

2020-09-22 21:00 927

Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual ...

2020-09-22 20:53 936

New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes

RALEIGH, North Carolina, Sept. 22, 2020 /PRNewswire/ -- According to new data presented at the 56th European Association for the Study of Diabetes (EASD) annual meeting, the GlycoMark blood test reflects beta-cell functional mass, which is important in identifying prediabetic individuals with the...

2020-09-22 19:00 840

TCM Lianhua Qingwen Capsule approved for registration in Mauritius

SHIJIAZHUANG, China, Sept. 22, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. (SHE: 002603) announced on Tuesday that it has received a registration approval issued by the Ministry of Health and Wellness ofMauritius, indicating Lianhua Qingwen Capsule has been registered in accordance with ...

2020-09-22 15:21 617

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...

2020-09-22 09:21 3580

Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round

Accelerating Commercialization of its Novel Pain Monitoring Solutions RAMAT GAN, Israel, Sept. 22, 2020 /PRNewswire/ -- Medasense Biometrics Ltd., developer of the NOL technology for pain-response monitoring, today announced that it has raised$18M in a series C round, from Sabadell Asabys venture...

2020-09-22 06:30 1382

Ortho Awarded BARDA Contract to Accelerate Antigen Test Development and Additional SARS-CoV-2 Antibody Test Milestones

RARITAN, N.J., Sept. 21, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced its continued collaboration with the Biomedical Advanced Research and Development Authority ( BARDA), part of the Office of the Assistant Secretary for Preparedness an...

2020-09-21 21:00 1373

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administr...

2020-09-21 20:12 1642

Hyde Engineering + Consulting Announces New VP of Global Engineering

BOULDER, Colorado, Sept. 21, 2020 /PRNewswire/ -- Hyde Engineering + Consulting, Inc. (Hyde) announced thatSanjay Shah has accepted the position of Vice President of Global Engineering. Sanjay, based out of Hyde's office in Ahmedabad,India, will provide subject matter expertise in conceptual an...

2020-09-21 11:30 1538

Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...

2020-09-21 10:35 860

Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interes...

2020-09-21 09:25 1599

Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2020-09-21 08:00 3381

Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2020-09-21 08:00 3648

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Not intended for US-, Canada- and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print inThe New England Journal of...

2020-09-18 15:00 9130

PolyU designs new dual-task exercise for stroke patients to effectively reduce the risk of falls and fall-related injuries

HONG KONG, Sept. 18, 2020 /PRNewswire/ -- Stroke is the fourth leading cause of death inHong Kong[1], hospitalising around 25,000 people each year[2]. Despite declines in stroke mortality over the past years, it remains one of the major causes of adult disability, greatly affecting the daily live...

2020-09-18 10:08 2275

First patient in treatment in RhoVac's clinical phase IIb study in Sweden

STOCKHOLM, Sept. 17, 2020 /PRNewswire/ --  RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...

2020-09-17 23:51 2508

Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commerc...

2020-09-17 20:25 2366

Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2020

HONG KONG, Sept. 17, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 20...

2020-09-17 19:00 12761
12345 ... 190